S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
OTCMKTS:PBIO

Pressure BioSciences - PBIO Stock Forecast, Price & News

$1.39
0.00 (0.00%)
(As of 03/24/2023 08:52 PM ET)
Add
Compare
Today's Range
$1.38
$1.42
50-Day Range
$1.25
$2.14
52-Week Range
$0.91
$2.40
Volume
8,500 shs
Average Volume
23,284 shs
Market Capitalization
$21.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PBIO stock logo

About Pressure BioSciences (OTCMKTS:PBIO) Stock

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

Receive PBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PBIO Stock News Headlines

Modern Day Options Trading For Beginners!
These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. pixel
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Normal Blood Pressure Numbers According to Age
Pressure BioSciences, Inc. (PBIO)
See More Headlines
Receive PBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PBIO Company Calendar

Last Earnings
11/17/2020
Today
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PBIO
Employees
12
Year Founded
N/A

Profitability

Net Income
$-20,150,000.00
Net Margins
-1,078.50%
Pretax Margin
-1,078.43%

Debt

Sales & Book Value

Annual Sales
$2 million
Book Value
($2.63) per share

Miscellaneous

Free Float
13,804,000
Market Cap
$21.43 million
Optionable
Not Optionable
Beta
0.77

Key Executives

  • Mr. Richard T. Schumacher (Age 73)
    Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director
    Comp: $355.18k
  • Dr. Alexander V. Lazarev Ph.D. (Age 58)
    Chief Science Officer
    Comp: $202.34k
  • Dr. Edmund Y. Ting Ph.D. (Age 68)
    Sc.D. Ph.D., Sr. VP of Engineering
    Comp: $256.92k
  • John B. Hollister
    Director of Sales & Marketing













PBIO Stock - Frequently Asked Questions

How have PBIO shares performed in 2023?

Pressure BioSciences' stock was trading at $1.30 at the beginning of the year. Since then, PBIO stock has increased by 6.9% and is now trading at $1.39.
View the best growth stocks for 2023 here
.

Are investors shorting Pressure BioSciences?

Pressure BioSciences saw a decline in short interest in March. As of March 15th, there was short interest totaling 1,700 shares, a decline of 71.2% from the February 28th total of 5,900 shares. Based on an average daily volume of 47,100 shares, the short-interest ratio is currently 0.0 days.
View Pressure BioSciences' Short Interest
.

How were Pressure BioSciences' earnings last quarter?

Pressure BioSciences, Inc. (OTCMKTS:PBIO) released its earnings results on Tuesday, November, 17th. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($2.20) by $1.18. The business earned $0.53 million during the quarter.
Read the conference call transcript
.

What other stocks do shareholders of Pressure BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pressure BioSciences investors own include Advanced Micro Devices (AMD), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Actinium Pharmaceuticals (ATNM), Anavex Life Sciences (AVXL), Aware (AWRE), Curaleaf (CURLF) and Walt Disney (DIS).

What is Pressure BioSciences' stock symbol?

Pressure BioSciences trades on the OTCMKTS under the ticker symbol "PBIO."

How do I buy shares of Pressure BioSciences?

Shares of PBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pressure BioSciences' stock price today?

One share of PBIO stock can currently be purchased for approximately $1.39.

How much money does Pressure BioSciences make?

Pressure BioSciences (OTCMKTS:PBIO) has a market capitalization of $21.43 million and generates $2 million in revenue each year. The company earns $-20,150,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How can I contact Pressure BioSciences?

Pressure BioSciences' mailing address is 14 NORFOLK AVENUE, SOUTH EASTON MA, 02375. The official website for the company is www.pressurebiosciences.com. The company can be reached via phone at 508-230-1828, via email at ir@pressurebiosciences.com, or via fax at 508-230-1829.

This page (OTCMKTS:PBIO) was last updated on 3/27/2023 by MarketBeat.com Staff